202 related articles for article (PubMed ID: 17980406)
41. Phase II study of erlotinib in Japanese patients with advanced non-small cell lung cancer.
Takahashi T; Yamamoto N; Nukiwa T; Mori K; Tsuboi M; Horai T; Masuda N; Eguchi K; Mitsudomi T; Yokota S; Segawa Y; Ichinose Y; Fukuoka M; Saijo N
Anticancer Res; 2010 Feb; 30(2):557-63. PubMed ID: 20332470
[TBL] [Abstract][Full Text] [Related]
42. Phase II study of erlotinib in recurrent or metastatic endometrial cancer: NCIC IND-148.
Oza AM; Eisenhauer EA; Elit L; Cutz JC; Sakurada A; Tsao MS; Hoskins PJ; Biagi J; Ghatage P; Mazurka J; Provencher D; Dore N; Dancey J; Fyles A
J Clin Oncol; 2008 Sep; 26(26):4319-25. PubMed ID: 18591547
[TBL] [Abstract][Full Text] [Related]
43. Single-agent gefitinib in patients with untreated advanced non-small-cell lung cancer and poor performance status: a Minnie Pearl Cancer Research Network Phase II Trial.
Spigel DR; Hainsworth JD; Burkett ER; Burris HA; Yardley DA; Thomas M; Jones SF; Dickson NR; Scullin DC; Bradof JE; Rubinsak JR; Brierre JE; Greco FA
Clin Lung Cancer; 2005 Sep; 7(2):127-32. PubMed ID: 16179100
[TBL] [Abstract][Full Text] [Related]
44. Phase II study of preoperative gefitinib in clinical stage I non-small-cell lung cancer.
Lara-Guerra H; Waddell TK; Salvarrey MA; Joshua AM; Chung CT; Paul N; Boerner S; Sakurada A; Ludkovski O; Ma C; Squire J; Liu G; Shepherd FA; Tsao MS; Leighl NB
J Clin Oncol; 2009 Dec; 27(36):6229-36. PubMed ID: 19884551
[TBL] [Abstract][Full Text] [Related]
45. Gefitinib as a first-line therapy of advanced or metastatic adenocarcinoma of the lung in never-smokers.
Lee DH; Han JY; Lee HG; Lee JJ; Lee EK; Kim HY; Kim HK; Hong EK; Lee JS
Clin Cancer Res; 2005 Apr; 11(8):3032-7. PubMed ID: 15837758
[TBL] [Abstract][Full Text] [Related]
46. An open-label, single-arm phase two trial of gefitinib in patients with advanced or metastatic castration-resistant prostate cancer.
Pezaro C; Rosenthal MA; Gurney H; Davis ID; Underhill C; Boyer MJ; Kotasek D; Solomon B; Toner GC
Am J Clin Oncol; 2009 Aug; 32(4):338-41. PubMed ID: 19363437
[TBL] [Abstract][Full Text] [Related]
47. Phase II study of gefitinib adaptive dose escalation to skin toxicity in recurrent or metastatic squamous cell carcinoma of the head and neck.
Perez CA; Song H; Raez LE; Agulnik M; Grushko TA; Dekker A; Stenson K; Blair EA; Olopade OI; Seiwert TY; Vokes EE; Cohen EE
Oral Oncol; 2012 Sep; 48(9):887-92. PubMed ID: 22513208
[TBL] [Abstract][Full Text] [Related]
48. Phase II study of gefitinib for the treatment of recurrent and metastatic nasopharyngeal carcinoma.
Chua DT; Wei WI; Wong MP; Sham JS; Nicholls J; Au GK
Head Neck; 2008 Jul; 30(7):863-7. PubMed ID: 18213730
[TBL] [Abstract][Full Text] [Related]
49. Analysis of the EGFR mutation status in head and neck squamous cell carcinoma before treatment with Gefitinib.
Bontognali S; Pless M; Brutsche MH; Fischer C; Rochlitz C; Buess M
Onkologie; 2013; 36(4):161-6. PubMed ID: 23548963
[TBL] [Abstract][Full Text] [Related]
50. Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected].
Stewart JS; Cohen EE; Licitra L; Van Herpen CM; Khorprasert C; Soulieres D; Vodvarka P; Rischin D; Garin AM; Hirsch FR; Varella-Garcia M; Ghiorghiu S; Hargreaves L; Armour A; Speake G; Swaisland A; Vokes EE
J Clin Oncol; 2009 Apr; 27(11):1864-71. PubMed ID: 19289630
[TBL] [Abstract][Full Text] [Related]
51. A phase II study of gefitinib for patients with advanced HER-1 expressing synovial sarcoma refractory to doxorubicin-containing regimens.
Ray-Coquard I; Le Cesne A; Whelan JS; Schoffski P; Bui BN; Verweij J; Marreaud S; van Glabbeke M; Hogendoorn P; Blay JY
Oncologist; 2008 Apr; 13(4):467-73. PubMed ID: 18448563
[TBL] [Abstract][Full Text] [Related]
52. A phase II study of patients with metastatic or locoregionally recurrent nasopharyngeal carcinoma and evaluation of plasma Epstein-Barr virus DNA as a biomarker of efficacy.
Ma B; Hui EP; King A; To KF; Mo F; Leung SF; Kam M; Lo YM; Zee B; Mok T; Ahuja A; Chan AT
Cancer Chemother Pharmacol; 2008 Jun; 62(1):59-64. PubMed ID: 17762933
[TBL] [Abstract][Full Text] [Related]
53. Role of gefitinib in patients with recurrent or metastatic cervical carcinoma ineligible or refractory to systemic chemotherapy: first study from Asia.
Sharma DN; Rath GK; Julka PK; Gandhi AK; Jagadesan P; Kumar S
Int J Gynecol Cancer; 2013 May; 23(4):705-9. PubMed ID: 23466569
[TBL] [Abstract][Full Text] [Related]
54. A phase II, open-label study of gefitinib (IRESSA) in patients with locally advanced, metastatic, or relapsed renal-cell carcinoma.
Jermann M; Stahel RA; Salzberg M; Cerny T; Joerger M; Gillessen S; Morant R; Egli F; Rhyner K; Bauer JA; Pless M
Cancer Chemother Pharmacol; 2006 Apr; 57(4):533-9. PubMed ID: 16052341
[TBL] [Abstract][Full Text] [Related]
55. Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer.
Baselga J; Albanell J; Ruiz A; Lluch A; Gascón P; Guillém V; González S; Sauleda S; Marimón I; Tabernero JM; Koehler MT; Rojo F
J Clin Oncol; 2005 Aug; 23(23):5323-33. PubMed ID: 15939921
[TBL] [Abstract][Full Text] [Related]
56. A phase II trial of gefitinib (Iressa, ZD1839) in stage IV and recurrent renal cell carcinoma.
Dawson NA; Guo C; Zak R; Dorsey B; Smoot J; Wong J; Hussain A
Clin Cancer Res; 2004 Dec; 10(23):7812-9. PubMed ID: 15585612
[TBL] [Abstract][Full Text] [Related]
57. Phase II study of gefitinib in patients with advanced salivary gland cancers.
Jakob JA; Kies MS; Glisson BS; Kupferman ME; Liu DD; Lee JJ; El-Naggar AK; Gonzalez-Angulo AM; Blumenschein GR
Head Neck; 2015 May; 37(5):644-9. PubMed ID: 24585506
[TBL] [Abstract][Full Text] [Related]
58. Clinical and toxicity predictors of response and progression to temsirolimus in women with recurrent or metastatic endometrial cancer.
Goodwin RA; Jamal R; Tu D; Walsh W; Dancey J; Oza AM; Elit L; Eisenhauer EA
Gynecol Oncol; 2013 Nov; 131(2):315-20. PubMed ID: 23938374
[TBL] [Abstract][Full Text] [Related]
59. Long-term effect of gefitinib (ZD1839) on squamous cell carcinoma of the lung.
Kozuki T; Kiura K; Ueoka H; Tabata M; Date H; Hamazaki S; Bessho A; Tanimoto M
Anticancer Res; 2004; 24(1):393-6. PubMed ID: 15015626
[TBL] [Abstract][Full Text] [Related]
60. A phase II trial of gefitinib for recurrent or metastatic cancer of the esophagus or gastroesophageal junction.
Adelstein DJ; Rodriguez CP; Rybicki LA; Ives DI; Rice TW
Invest New Drugs; 2012 Aug; 30(4):1684-9. PubMed ID: 21863238
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
